A combination of PDL-1 inhibitor atezolizumab (tradename Tecentriq) with BRAF inhibitor vemurafenib (tradename Zelboraf) and MEK inhibitor cobimetinib (tradename Cotellic) was approved in 2020 for unresectable or metastatic BRAF V600 positive melanoma [31]. Here, BRAF is linked to melanoma.